| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/25/2023 | 79.72% | Piper Sandler | $43 → $42 | Maintains | Overweight |
| 05/10/2023 | 96.83% | Piper Sandler | $45 → $46 | Maintains | Overweight |
| 01/23/2023 | 101.11% | Piper Sandler | $40 → $47 | Maintains | Overweight |
| 08/31/2022 | 62.6% | Piper Sandler | $33 → $38 | Maintains | Overweight |
| 04/13/2021 | 71.16% | Jefferies | $25 → $40 | Upgrades | Hold → Buy |
| 06/16/2020 | 32.65% | Piper Sandler | $25 → $31 | Upgrades | Neutral → Overweight |
| 06/15/2020 | 2.7% | Jefferies | → $24 | Reinstates | → Hold |
| 04/16/2020 | 2.7% | Stifel | $25 → $24 | Maintains | Hold |
| 11/07/2019 | -1.58% | Stifel | $55 → $23 | Downgrades | Buy → Hold |
| 11/06/2019 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/17/2018 | 169.58% | Mizuho | $61 → $63 | Maintains | Buy |
| 11/12/2018 | 178.13% | B. Riley Securities | $68 → $65 | Maintains | Buy |
What is the target price for Supernus Pharmaceuticals (SUPN)?
The latest price target for Supernus Pharmaceuticals (NASDAQ: SUPN) was reported by Piper Sandler on October 25, 2023. The analyst firm set a price target for $42.00 expecting SUPN to rise to within 12 months (a possible 79.72% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Supernus Pharmaceuticals (SUPN)?
The latest analyst rating for Supernus Pharmaceuticals (NASDAQ: SUPN) was provided by Piper Sandler, and Supernus Pharmaceuticals maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Supernus Pharmaceuticals (SUPN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on October 25, 2023 so you should expect the next rating to be made available sometime around October 25, 2024.
Is the Analyst Rating Supernus Pharmaceuticals (SUPN) correct?
While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a maintained with a price target of $43.00 to $42.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $23.37, which is out of the analyst's predicted range.